148 related articles for article (PubMed ID: 34772490)
1. Impact of Anti-HLA De Novo Donor Specific Antibody on Graft Outcomes in Pancreas Transplantation: A Meta-Analysis.
Khan SM; Sumbal R; Schenk AD
Transplant Proc; 2021 Dec; 53(10):3022-3029. PubMed ID: 34772490
[TBL] [Abstract][Full Text] [Related]
2. Effect of blood transfusion post kidney transplantation on de novo human leukocytes antigen donor-specific antibody development and clinical outcomes in kidney transplant recipients: A systematic review and meta-analysis.
Kang ZY; Ma S; Liu W; Liu C
Transpl Immunol; 2023 Jun; 78():101801. PubMed ID: 36841513
[TBL] [Abstract][Full Text] [Related]
3. Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation.
Ladowski JM; Mullins H; Romine M; Kloda D; Young C; Hauptfeld-Dolejsek V; Houp J; Locke J
Hum Immunol; 2021 Mar; 82(3):139-146. PubMed ID: 33390268
[TBL] [Abstract][Full Text] [Related]
4. Role of de novo donor-specific anti-HLA antibodies in kidney graft failure: A case-control study.
Castro A; Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
HLA; 2017 Nov; 90(5):267-275. PubMed ID: 28776960
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Pancreas Transplant Recipients With De Novo Donor-specific Antibodies.
Parajuli S; Alagusundaramoorthy S; Aziz F; Garg N; Redfield RR; Sollinger H; Kaufman D; Djamali A; Odorico J; Mandelbrot D
Transplantation; 2019 Feb; 103(2):435-440. PubMed ID: 29994978
[TBL] [Abstract][Full Text] [Related]
6. Human leukocyte antigen epitope mismatch loads and the development of de novo donor-specific antibodies in cardiothoracic organ transplantation.
Bedford A; Jervis S; Worthington J; Lowe M; Poulton K
Int J Immunogenet; 2022 Feb; 49(1):30-38. PubMed ID: 34904369
[TBL] [Abstract][Full Text] [Related]
7. Impact of de novo donor-specific HLA antibodies on pediatric kidney transplant prognosis in patients with acute declined or stable allograft function.
Fylaktou A; Karava V; Vittoraki A; Zampetoglou A; Papachristou M; Antoniadis N; Iniotaki A; Mitsioni A; Printza N
Pediatr Transplant; 2022 May; 26(3):e14221. PubMed ID: 34994049
[TBL] [Abstract][Full Text] [Related]
8. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861
[TBL] [Abstract][Full Text] [Related]
9. Analysis of predictive and preventive factors for de novo DSA in kidney transplant recipients.
Hirai T; Furusawa M; Omoto K; Ishida H; Tanabe K
Transplantation; 2014 Aug; 98(4):443-50. PubMed ID: 24717219
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
[TBL] [Abstract][Full Text] [Related]
11. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant de novo non donor-specific HLA antibodies are not associated with poor graft outcome in non-sensitized pediatric recipients of kidney transplantation.
Cioni M; Comoli P; Tagliamacco A; Innocente A; Basso S; Fontana I; Magnasco A; Trivelli A; Nocco A; Macchiagodena M; Catenacci L; Klersy C; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Nocera A
Transpl Immunol; 2021 Apr; 65():101375. PubMed ID: 33610675
[TBL] [Abstract][Full Text] [Related]
13. Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study.
Everly MJ; Briley KP; Haisch CE; Dieplinger G; Bolin P; Kendrick SA; Morgan C; Maldonado AQ; Rebellato LM
Transpl Int; 2017 Jun; 30(6):566-578. PubMed ID: 28211192
[TBL] [Abstract][Full Text] [Related]
14. Changes in successive measures of de novo donor-specific anti-human leukocyte antigen antibodies intensity and the development of allograft dysfunction.
Dieplinger G; Everly MJ; Rebellato LM; Haisch CE; Briley KP; Bolin P; Kendrick WT; Kendrick SA; Morgan C; Harland RC; Terasaki PI
Transplantation; 2014 Nov; 98(10):1097-104. PubMed ID: 24911039
[TBL] [Abstract][Full Text] [Related]
15. Early immunosuppression treatment correlates with later de novo donor-specific antibody development after kidney and pancreas transplantation.
Pelletier RP; Rajab AA; Diez A; DiPaola NR; Bumgardner GL; Elkhammas EA; Henry ML
Clin Transplant; 2015 Dec; 29(12):1119-27. PubMed ID: 26382932
[TBL] [Abstract][Full Text] [Related]
16. The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients.
Sharma A; Taverniti A; Graf N; Teixeira-Pinto A; Lewis JR; Lim WH; Alexander SI; Durkan A; Craig JC; Wong G
Pediatr Nephrol; 2020 Jun; 35(6):1061-1068. PubMed ID: 32065279
[TBL] [Abstract][Full Text] [Related]
17. Prospective De Novo Donor-Specific Antibody Monitoring in Renal Transplant Patients.
Fylaktou A; Sampani E; Kasimatis E; Nikolaidou V; Dimitriadis C; Anastasiou A; Papachristou M; Chatzika G; Papagianni A
Transplant Proc; 2021 Nov; 53(9):2765-2768. PubMed ID: 34598809
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation.
Bamoulid J; Roodenburg A; Staeck O; Wu K; Rudolph B; Brakemeier S; Halleck F; Lehner L; Schönemann C; Lachmann N; Budde K
Transplantation; 2017 Sep; 101(9):2165-2174. PubMed ID: 27653301
[TBL] [Abstract][Full Text] [Related]
19. De novo donor-specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA?
Moayedi Y; Fan CS; Tinckam KJ; Ross HJ; McCaughan JA
Clin Transplant; 2018 Nov; 32(11):e13416. PubMed ID: 30276870
[TBL] [Abstract][Full Text] [Related]
20. Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients.
Charnaya O; Jones J; Philogene MC; Chiang PY; Segev DL; Massie AB; Garonzik-Wang J
Pediatr Nephrol; 2021 Dec; 36(12):3971-3979. PubMed ID: 34100108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
